Abbonarsi

Persistent esophageal changes after histologic remission in eosinophilic esophagitis - 04/04/24

Doi : 10.1016/j.jaci.2023.12.012 
Melanie A. Ruffner, MD, PhD a, b, , Tetsuo Shoda, MD, PhD c, , Megha Lal, PhD b, Zoe Mrozek, BS b, Amanda B. Muir, MD a, d, Jonathan M. Spergel, MD, PhD a, b, Evan S. Dellon, MD e, Marc E. Rothenberg, MD, PhD c
a Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa 
b Division of Allergy & Immunology, Children’s Hospital of Philadelphia, Philadelphia, Pa 
c Department of Pediatrics, Division of Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 
d Division of Gastroenterology, Hepatology, and Nutrition, Children’s Hospital of Philadelphia, Philadelphia, Pa 
e Department of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC 

Corresponding author: Melanie A. Ruffner, MD, PhD, Children’s Hospital of Philadelphia, 3615 Civic Center Blvd, ARC 1202, Philadelphia, PA 19104.Children’s Hospital of Philadelphia3615 Civic Center BlvdARC 1202PhiladelphiaPA19104

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

Eosinophilic esophagitis (EoE) is characterized by persistent or relapsing allergic inflammation, and both clinical and histologic features of esophageal inflammation persist over time in most individuals. Mechanisms contributing to EoE relapse are not understood, and chronic EoE-directed therapy is therefore required to prevent long-term sequelae.

Objective

We investigated whether EoE patients in histologic remission have persistent dysregulation of esophageal gene expression.

Methods

Esophageal biopsy samples from 51 pediatric and 52 adult subjects with EoE in histopathologic remission (<15 eosinophils per high-power field [eos/hpf]) and control (48 pediatric and 167 adult) subjects from multiple institutions were subjected to molecular profiling by the EoE diagnostic panel, which comprises a set of 94 esophageal transcripts differentially expressed in active EoE.

Results

Defining remission as <15 eos/hpf, we identified 51 and 32 differentially expressed genes in pediatric and adult EoE patients compared to control individuals, respectively (false discovery rate < 0.05). Using the stringent definition of remission (0 eos/hpf), the adult and pediatric cohorts continued to have 18 and 25 differentially expressed genes (false discovery rate < 0.05). Among 6 shared genes between adults and children, CDH26 was upregulated in both children and adults; immunohistochemistry demonstrated increased cadherin 26 staining in the epithelium of EoE patients in remission compared to non-EoE controls. In the adult cohort, POSTN expression correlated with the endoscopic reference system score (Spearman r = 0.35, P = .011), specifically correlating with the rings’ endoscopic reference system subscore (r = 0.53, P = .004).

Conclusion

We have identified persistent EoE-associated esophageal gene expression in patients with disease in deep remission. These data suggest potential inflammation-induced epigenetic mechanisms may influence gene expression during remission in EoE and provide insight into possible mechanisms that underlie relapse in EoE.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Eosinophilic esophagitis, diagnostic panel, EoE transcriptome, eosinophil, molecular diagnostics, predictive medicine, remission, inflammatory memory

Abbreviations used : Ct, DEG, EDP, EoE, EoEHSS, eos, EREFS, FDR, hpf, scRNA-Seq


Mappa


© 2023  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 153 - N° 4

P. 1063-1072 - aprile 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • IgE and anaphylaxis specific to the carbohydrate alpha-gal depend on IL-4
  • Miriam Hils, Nils Hoffard, Caterina Iuliano, Luisa Kreft, Neera Chakrapani, Kyra Swiontek, Konrad Fischer, Bernadette Eberlein, Martin Köberle, Jörg Fischer, Christiane Hilger, Caspar Ohnmacht, Susanne Kaesler, Florian Wölbing, Tilo Biedermann
| Articolo seguente Articolo seguente
  • Meta-analysis of ACE inhibitor–induced angioedema identifies novel risk locus
  • Carina M. Mathey, Carlo Maj, Niclas Eriksson, Kristi Krebs, Julia Westmeier, Friederike S. David, Maria Koromina, Annika B. Scheer, Nora Szabo, Bettina Wedi, Dorothea Wieczorek, Philipp M. Amann, Harald Löffler, Lukas Koch, Clemens Schöffl, Heinrich Dickel, Nomun Ganjuur, Thorsten Hornung, Timo Buhl, Jens Greve, Gerda Wurpts, Emel Aygören-Pürsün, Michael Steffens, Stefan Herms, Stefanie Heilmann-Heimbach, Per Hoffmann, Börge Schmidt, Laven Mavarani, Trine Andresen, Signe Bek Sørensen, Vibeke Andersen, Ulla Vogel, Mikael Landén, Cynthia M. Bulik, Estonian Biobank Research Team, DBDS Genomic Consortium, Anette Bygum, Patrik K.E. Magnusson, Christian von Buchwald, Pär Hallberg, Sisse Rye Ostrowski, Erik Sørensen, Ole B. Pedersen, Henrik Ullum, Christian Erikstrup, Henning Bundgaard, Lili Milani, Eva Rye Rasmussen, Mia Wadelius, Jonas Ghouse, Bernhardt Sachs, Markus M. Nöthen, Andreas J. Forstner

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.